Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 19 years~* Ability to give informed consent~* Documented stable CAD with a significant lesion in a native coronary artery amenable to PCI with one stent~* Planned single vessel intervention~Exclusion Criteria:~* Myocardial infarction or unstable angina within the prior 7 days~* Target lesion is a chronic total occlusion (present for longer than 3 months)~* Target lesion with angiographically visible thrombus or in-stent thrombosis~* Target lesion is in a bypass graft~* Planned use of a GP IIb/IIIa inhibitor or planned use of atherectomy including directional, rotational, or laser~* Known allergies or sensitivities to heparin, pork, or pork-containing products~* History of HIT~* Hemodynamic instability~* Stroke or Transient Ischemic Attack (TIA) in the prior 3 months~* Active bleeding or bleeding diathesis~* Trauma or major surgery in the preceding month or planned surgery or PCI within the 30 days after the index PCI~* Suspected aortic dissection~* Receiving oral anticoagulation therapy~* Receipt of LMWH or of UFH (except for that used during the diagnostic portion of the index procedure) within the prior 7 days~* ACT \> 200 prior to study drug administration~* Severe, untreated hypertension at the time of the index PCI procedure (systolic blood pressure of \> 180 mm Hg, diastolic blood pressure \> 90 mm Hg)~* Hemoglobin level of less than 10.0 g/dl or a hematocrit below 30%~* Platelet count of less than 100,000 per cubic millimeter or more than 600,000 per cubic millimeter~* Creatinine clearance \< 30 mL/min~* Any malignancy within the prior 5 years with the exception of non-melanoma skin cancers~* Prior enrollment in EMINENCE trial or currently receiving other experimental therapy~* Pregnant or lactating if subject is female~Substudy:~Inclusion:~* Ability to give informed consent~* Participation in the main study protocol~Exclusion:~-Inability to provide the blood specimens required by the substudy protocol

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 70 U/kg of unfractionated heparin given IV (Type: ACTIVE_COMPARATOR): Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
- 50 IU/KG of M118 (Type: EXPERIMENTAL): Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
- 75 IU/KG of M118 (Type: EXPERIMENTAL): Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
- 100 IU/KG of M118 (Type: EXPERIMENTAL): Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).